a friendly research notebook ~ two peptides, one stack
BPC-157 TB-500 is the Wolverine blend's two peptides — here is what their research actually shows.
One is a 15-amino-acid repair peptide; the other is a 7-amino-acid actin-binding fragment. We read each against its own studies, mark where the human data stop, and never pretend the combination has been tested when it hasn't.
Two peptides, one community nickname
BPC-157 TB-500 is the research-community pairing better known by its gym-forum nickname, the "Wolverine" blend. It is not one molecule. It is two distinct synthetic peptides put in the same conversation — and often the same vial — because each one touches a different part of how tissue repairs. BPC-157 is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419 Da) derived from a protein found in human gastric juice. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4, the body's principal actin-sequestering protein [3][4].
This site is a digest, not a dispensary. We summarize the peer-reviewed literature on each peptide, pair every number with the study it came from, and stay honest about one thing in particular: the blend itself — the two given together — has never been tested in a controlled study [8]. Everything below describes the components individually, in the species and models where they were actually studied.
The BPC-157 TB-500 stack: the Wolverine pairing, combined
The "Wolverine stack" idea is simple to state and harder to defend: combine BPC-157 and TB-500 and you get two repair signals at once. BPC-157 supplies a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2]. TB-500's LKKTETQ motif binds monomeric G-actin one-to-one and regulates the cytoskeletal dynamics that drive cell migration [3]. The two are described as acting through complementary but largely non-overlapping pathways, which is the entire rationale for pairing them.
That rationale is a theoretical extrapolation, not a finding. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies and never once mentions TB-500 or any combination [8]. If you came looking for proof the stack works, the honest answer is that the evidence is single-compound and mostly preclinical — and the BPC-157 TB-500 side effects and the tumor-signal concern deserve as much attention as the upside.
What is the Wolverine peptide blend?
Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere [9]. The name is a gym-forum nickname, not a brand or a defined drug.
What is the Wolverine peptide blend?
Search interest in the "wolverine peptide" runs high, but much of that volume is tangled up with the comic-book character. Stripped of the name, the wolverine peptide blend is just BPC-157 plus TB-500: two synthetic peptides marketed and discussed together as a regenerative pairing. There is no standardized composition. Commercial research vials are commonly labeled with a combined per-vial mass — for example 10 mg BPC-157 with 10 mg TB-500 — but no ratio has been clinically validated [9].
The two components occupy complementary nodes of a tissue-repair network in preclinical work. BPC-157 has been studied for cytoprotection, angiogenesis, and tendon and ligament repair in rodent models [1][2]; TB-500 and its parent protein Thymosin Beta-4 have been studied for cell migration, re-epithelialization, and wound healing in animal and biochemical models [3][4]. The blend as a single product, though, has not been tested in any controlled study.
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23 — the actin-binding region — of Thymosin Beta-4 [3]. The Wolverine blend pairs the two as a research-community tissue-repair "stack"; it is not a single chemical entity or an approved product [9].
What is the BPC-157 and TB-500 blend used for in research?
In preclinical work the two components occupy complementary repair roles: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models [1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models [3][4]. The assembled blend itself has not been tested in a controlled study [8].
How we read the evidence here
Three rules keep this notebook honest. First, every quantitative claim — a dose, a half-life, a count — is tied to a study you can look up in the full reference list. Second, when something has only been shown in rats or in a test tube, we say so plainly rather than letting it read like a human result. Third, the gaps get the same ink as the findings: no controlled blend trial, no validated human pharmacokinetics, and a standing tumor-signal concern around Thymosin Beta-4 [5].
If you want the mechanism detail and the study-by-study record, start with BPC-157 and TB-500 mechanisms; from there it is easy to see why researchers pair the two peptides and to weigh the BPC-157 vs. TB-500 differences side by side. For the numbers, the BPC-157 TB-500 dosage in animal studies is reported per body weight and per route. If your question is about safety, the long-term safety and tolerability page leads with the careful parts first. And if you are trying to understand whether any of this is legally available — including the WADA prohibition status and the FDA picture — the Wolverine legal status and FDA 503A category page lays out the present-tense regulatory picture.
Benefits, risks, and the evidence line
The rev3 corpus adds a plain-language BPC-157 TB-500 effects and safety page beside the existing side-effects research. Community reports stay anecdotal; cited cautions stay tied to the audited record.